Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 8/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.32 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.32 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.32 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.32 |
| ▸ | DGKA | P23743 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951942 | 0.86 | GABBR2 (0.33) | GABBR2GABRR1GABBR1ACHE | |
| SCHEMBL2952313 | 0.85 | GABBR2 (0.33) | GABBR2GABRR1GABBR1ACHE | |
| SCHEMBL1886722 | 0.83 | ALDH1A1 (0.32) | ACHE | |
| SCHEMBL2947858 | 0.82 | ACHE (0.46) | GABBR2GABRR1GABBR1ACHELPAR1 | |
| SCHEMBL2954561 | 0.81 | LMNA (0.33) | GABBR2GABRR1GABBR1ENPP2LPAR1 | |
| SCHEMBL2951139 | 0.80 | NAAA (0.35) | — | |
| SCHEMBL2949141 | 0.75 | GABBR2 (0.36) | GABBR2GABRR1GABBR1ENPP2LPAR1 | |
| SCHEMBL2951202 | 0.74 | GABBR2 (0.33) | GABBR2GABRR1GABBR1 | |
| SCHEMBL2947971 | 0.73 | GABBR2 (0.32) | GABBR2GABRR1GABBR1 | |
| SCHEMBL2951173 | 0.73 | GABBR2 (0.32) | GABBR2GABRR1GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7749985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2010-07-06 | — | — | US | claimed |
| US-20090286759-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2009-11-19 | — | — | US | claimed |
| US-7749985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090286759-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7585996-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080146526-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008033572-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286759-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, NAPEPLD, AASDHPPT | GABBR2 804/4885GABRR1 1069/4885GABBR1 598/4885 |
| US-20080146526-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, NAPEPLD, AASDHPPT | GABBR2 804/4885GABRR1 1069/4885GABBR1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.